Preface

IF 2.4 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Michael Kahn
{"title":"Preface","authors":"Michael Kahn","doi":"10.2174/187446721601221110105607","DOIUrl":null,"url":null,"abstract":"It is currently estimated that 57 million people (1 in 4 adults) in the Unites States have prediabetes, many of whom will develop diabetes in ensuing years unless significant modifications in lifestyle occur, including diet, weight loss, and exercise. Furthermore, a small but significant number may already be at risk for developing vascular disease. Hence, prediabetes constitutes a major international public health concern that threatens to increase dramatically given the growing prevalence of worldwide obesity. Prediabetes is also associatedwith considerable financial expenditure with higher rates of medical visits for hypertension, metabolic and renal complications, and general medical conditions. The national annual medical cost of prediabetes has been estimated to exceed $25 billion. Since it therefore impacts considerably an already burdened healthcare system, the recently passed Affordable Care Act is opportune, as it addresses the critical need for preventive approaches to this epidemic. A major factor contributing to the difficulty in ascertaining who has prediabetes pertains to the way it, as diabetes per se, has been defined. As discussed in greater detail in this issue, the diagnosis of prediabetes hasbeenpredicated on absolute criteria defined by blood glucose measurements, which is one of the reasons the American Diabetes Association adopted a range of HbA1c values as a basis for identifying those at risk for developing diabetes. However, as neither glucose nor HbA1c determinations may be sufficiently sensitive to diagnose early metabolic abnormalities precisely, the practitioner requires considerable judgment in assessing these subtle conditions. Thus, defining prediabetes categorically by relatively arbitrary threshold criteria may inadvertently lead to the failure to diagnose individuals with lower glucose levels who may still be at risk for progression to diabetes or cardiovascular disease. Rather than viewing the evolving disease process as a continuum, the traditional dichotomous approach to definingmetabolic entitiesmost likely addresses only a small segment of a much larger problem and hence underestimates the considerable prevalence of this condition. One potential approach for overcoming the uncertainty associated with absolute diagnostic criteria is the use of a “personalized profile,” which would","PeriodicalId":10865,"journal":{"name":"Current molecular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular pharmacology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/187446721601221110105607","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

It is currently estimated that 57 million people (1 in 4 adults) in the Unites States have prediabetes, many of whom will develop diabetes in ensuing years unless significant modifications in lifestyle occur, including diet, weight loss, and exercise. Furthermore, a small but significant number may already be at risk for developing vascular disease. Hence, prediabetes constitutes a major international public health concern that threatens to increase dramatically given the growing prevalence of worldwide obesity. Prediabetes is also associatedwith considerable financial expenditure with higher rates of medical visits for hypertension, metabolic and renal complications, and general medical conditions. The national annual medical cost of prediabetes has been estimated to exceed $25 billion. Since it therefore impacts considerably an already burdened healthcare system, the recently passed Affordable Care Act is opportune, as it addresses the critical need for preventive approaches to this epidemic. A major factor contributing to the difficulty in ascertaining who has prediabetes pertains to the way it, as diabetes per se, has been defined. As discussed in greater detail in this issue, the diagnosis of prediabetes hasbeenpredicated on absolute criteria defined by blood glucose measurements, which is one of the reasons the American Diabetes Association adopted a range of HbA1c values as a basis for identifying those at risk for developing diabetes. However, as neither glucose nor HbA1c determinations may be sufficiently sensitive to diagnose early metabolic abnormalities precisely, the practitioner requires considerable judgment in assessing these subtle conditions. Thus, defining prediabetes categorically by relatively arbitrary threshold criteria may inadvertently lead to the failure to diagnose individuals with lower glucose levels who may still be at risk for progression to diabetes or cardiovascular disease. Rather than viewing the evolving disease process as a continuum, the traditional dichotomous approach to definingmetabolic entitiesmost likely addresses only a small segment of a much larger problem and hence underestimates the considerable prevalence of this condition. One potential approach for overcoming the uncertainty associated with absolute diagnostic criteria is the use of a “personalized profile,” which would
前言
目前估计,美国有5700万人(四分之一的成年人)患有糖尿病前期,除非生活方式发生重大改变,包括饮食、减肥和锻炼,否则其中许多人将在未来几年患上糖尿病。此外,一小部分人可能已经有患血管疾病的风险。因此,糖尿病前期是一个主要的国际公共卫生问题,鉴于全球肥胖的日益普遍,这一问题可能会急剧增加。糖尿病前期还与可观的财政支出有关,高血压、代谢和肾脏并发症以及一般医疗状况的就诊率较高。据估计,全国每年糖尿病前期的医疗费用超过250亿美元。因此,由于它对已经负担沉重的医疗系统产生了相当大的影响,最近通过的《平价医疗法案》是合适的,因为它解决了对这一流行病采取预防措施的迫切需要。导致难以确定谁患有糖尿病前期的一个主要因素与糖尿病本身的定义方式有关。正如本期文章中更详细讨论的那样,糖尿病前期的诊断是基于血糖测量定义的绝对标准,这也是美国糖尿病协会采用一系列HbA1c值作为识别糖尿病风险人群的基础的原因之一。然而,由于葡萄糖和HbA1c的测定都不足以准确诊断早期代谢异常,因此从业者在评估这些微妙的情况时需要相当大的判断。因此,通过相对任意的阈值标准明确定义糖尿病前期可能会无意中导致无法诊断出葡萄糖水平较低的个体,这些个体可能仍有发展为糖尿病或心血管疾病的风险。传统的二分法定义代谢实体的方法很可能只解决了更大问题的一小部分,因此低估了这种疾病的相当普遍性,而不是将疾病的演变过程视为一个连续体。克服与绝对诊断标准相关的不确定性的一种潜在方法是使用“个性化档案”
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current molecular pharmacology
Current molecular pharmacology Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
CiteScore
4.90
自引率
3.70%
发文量
112
期刊介绍: Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes full-length/mini reviews, original research articles and thematic issues on molecular pharmacology. Current Molecular Pharmacology is an essential journal for every scientist who is involved in drug design and discovery, target identification, target validation, preclinical and clinical development of drugs therapeutically useful in human disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信